Primary prevention of cardiovascular disease with HRT

Women's Health

Volumn 8, Issue 1, 2012, Pages 63-74

  Maclaran, Kate ^a   Stevenson, John C ^a,b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

coronary heart disease; HRT; observational studies; randomized clinical trial; stroke; venous thromboembolis

Indexed keywords

CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN; GESTAGEN; LASOFOXIFENE; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; NANDROLONE DERIVATIVE; NORGESTREL; PLACEBO; PREGNANE DERIVATIVE; PROGESTERONE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TIBOLONE;

ATHEROSCLEROSIS; BREAST CANCER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DYSLIPIDEMIA; ENZYME INHIBITION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HORMONE SUBSTITUTION; HUMAN; NONHUMAN; OUTCOME ASSESSMENT; POSTMENOPAUSE OSTEOPOROSIS; PRIMARY PREVENTION; REVIEW; RISK ASSESSMENT; RISK REDUCTION; STROKE; TREATMENT DURATION; VENOUS THROMBOEMBOLISM;

ADULT; AGE FACTORS; CARDIOVASCULAR DISEASES; ESTROGEN REPLACEMENT THERAPY; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; MENOPAUSE; MIDDLE AGED; OSTEOPOROSIS; PRIMARY PREVENTION; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; WOMEN'S HEALTH;

EID: 83755167942     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/whe.11.87     Document Type: Review

References (103)

1. Kannel WB, Hjortland MC, McNamara PM, Gordon T. Menopause and risk of cardiovascular disease: the Framingham study. Ann. Intern. Med. 85, 447-452 (1976).
2. Anand S, Islam S, Rosengren A et al. Risk factors for myocardial infarction in women and men: insights from the INTERHEART study. Eur. Heart J. 29, 932-940 (2008). (Pubitemid 351499478)
3. Jacobsen BK, Knutsen SF, Fraser GE. Age at natural menopause and total mortality and mortality from ischemic heart disease: the Adventist Health Study. J. Clin. Epidemiol. 52, 303-307 (1999). (Pubitemid 29305302)
4. Rivera CM, Grossardt BR, Rhodes DJ et al. Increased cardiovascular mortality after early bilateral oophorectomy. Menopause 16, 15-23 (2009).
5. Rocca WA, Grossardt BR, Miller VM, Shuster LT, Brown RD Jr. Premature menopause or early menopause and risk of ischemic stroke. Menopause doi:10.1097/ gme.0b013e31822a9937 (2011) (Epub ahead of print).
6. Vaidya D, Becker DM, Bittner V, Mathias RA, Ouyang P. Ageing, menopause, and ischemic heart disease mortality in England, Wales, and the United States: modeling study of national mortality data. BMJ 343, d5170 (2011).
7. Rossouw JE, Anderson GL, Prentice RL et al. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288, 321-333 (2002). (Pubitemid 34761611)
8. Stevenson JC, Hodis HN, Pickar JH, Lobo RA. Coronary heart disease and menopause management: the swinging pendulum of HRT. Atherosclerosis 207, 336-340 (2009).
9. Rossouw JE, Prentice RL, Manson JE et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 297, 1465-1477 (2007). (Pubitemid 46556472)
10. LaCroix AZ, Chlebowski RT, Manson JE et al. WHI Investigators. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA 305, 1305-1314 (2011).
11. Stevenson JC. HRT and cardiovascular disease. Best Pract. Res. Clin. Obstet. Gynaecol. 23, 109-120 (2009).
12. Stevenson JC, Crook D, Godsland IF. Influence of age and menopause on serum lipids and lipoproteins in healthy women. Atherosclerosis 98, 83-90 (1993). (Pubitemid 23010426)
13. Spencer CP, Godsland IF, Stevenson JC. Is there a menopausal metabolic syndrome? Gynaecol. Endocrinol. 11, 341-355 (1997).
14. The Writing Group for the PEPI trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/ Progestin Interventions (PEPI) Trial. JAMA 273, 199-208 (1995).
15. Darling GM, Johns JA, McCloud PI, Davis SR. Estrogen and progestin compared with simvastatin for hypercholesterolemia in postmenopausal women. N. Engl. J. Med. 337, 595-601 (1997). (Pubitemid 27360759)
16. Shwaery GT, Vita JA, Keaney JF Jr. Antioxidant protection of LDL by physiological concentrations of 17 beta-estradiol. Requirement for estradiol modification. Circulation 95, 1378-1385 (1997). (Pubitemid 27142793)
17. Spencer CP, Godsland IF, Cooper AJ, Ross D, Whitehead MI, Stevenson JC. Effects of oral and transdermal 17b estradiol with cyclical oral norethindrone acetate on insulin sensitivity, secretion, and elimination in postmenopausal women. Metabolism 49, 742-747 (2000). (Pubitemid 30354581)
18. Gambacciani M, Ciaponi M, Cappagli B et al. Body weight, body fat distribution, and hormonal replacement therapy in early postmenopausal women. J. Clin. Endocrinol. Metab. 82, 414-417 (1997). (Pubitemid 27068603)
19. Clarkson TB, Appt SE. Controversies about HRT-lessons from monkey models. Maturitas 51, 64-74 (2005).
20. Holm P, Andersen HL, Andersen MR, Erhardtsen E, Stender S. The direct antiatherogenic effect of estrogen is present, absent, or reversed, depending on the state of the arterial endothelium. A time course study in cholesterol-clamped rabbits. Circulation 100, 1727-1733 (1999). (Pubitemid 29485256)
21. Billon-Galés A, Fontaine C, Douin-Echinard V et al. Endothelial estrogen receptor-alpha plays a crucial role in the atheroprotective action of 17b estradiol in low-density lipoprotein receptor-deficient mice. Circulation 120, 2567-2576 (2009).
22. Adams MR, Kaplan JR, Manuck SB et al. Inhibition of coronary artery atherosclerosis by 17b estradiol in ovariectomized monkeys. Lack of an effect of added progesterone. Arteriosclerosis 10, 1051-1057 (1990).
23. Wakatsuki A, Okatani Y, Ikenoue N, Fukaya T. Effect of medroxyprogesterone acetate on endothelium-dependent vasodilation in postmenopausal women receiving estrogen. Circulation 104, 1773-1778 (2001). (Pubitemid 32963341)
24. Favre J, Gao J, Henry JP et al. Endothelial estrogen receptor a plays an essential role in the coronary and myocardial protective effects of estradiol in ischemia/reperfusion. Arterioscler. Thromb. Vasc. Biol. 30, 2562-2567 (2010).
25. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev. Med. 20, 47-63 (1991).
26. Barrett-Connor E, Grady D. Hormone replacement therapy, heart disease, and other considerations. Annu. Rev. Public Health 19, 55-72 (1998). (Pubitemid 28279924)
27. Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann. Intern. Med. 133, 933-941 (2000). (Pubitemid 32003509)
28. Hodis HN, Mack WJ, Lobo RA et al.; Estrogen in the Prevention of Atherosclerosis Trial Research Group. Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 135, 939-953 (2001). (Pubitemid 33131615)
29. Anderson GL, Limacher M, Assaf AR et al.; Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291, 1701-1712 (2004). (Pubitemid 38489892)
30. Prentice RL, Langer R, Stefanick ML et al.; Women's Health Initiative Investigators. Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial. Am. J. Epidemiol. 162, 404-414 (2005). (Pubitemid 41191425)
31. Prentice RL, Langer RD, Stefanick ML et al.; Women's Health Initiative Investigators. Combined analysis of Women's Health Initiative observational and clinical trial data on postmenopausal hormone treatment and cardiovascular disease. Am. J. Epidemiol. 163, 589-599 (2006).
32. Manson JE, Allison MA, Rossouw JE et al.; WHI and WHI-CACS Investigators. Estrogen therapy and coronary-artery calcification. N. Engl. J. Med. 356, 2591-2602 (2007). (Pubitemid 46961004)
33. Matthews KA, Kuller LH, Wing RR, Meilahn EN, Plantinga P. Prior to use of estrogen replacement therapy, are users healthier than nonusers? Am. J. Epidemiol. 143, 971-978 (1996). (Pubitemid 26140324)
34. Grodstein F, Manson JE, Stampfer MJ. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J. Womens Health (Larchmt) 15, 35-44 (2006). (Pubitemid 43192860)
35. Hernán MA, Alonso A, Logan R et al. Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease. Epidemiology 19, 766-779 (2008).
36. Tuomikoski P, Ylikorkala O, Mikkola TS. Menopausal hot flushes and vascular health. Ann. Med. 43, 283-291 (2011).
37. Gast GC, Grobbee DE, Pop VJ et al. Menopausal complaints are associated with cardiovascular risk factors. Hypertension 51, 1492-1498 (2008).
38. Thurston RC, Sutton-Tyrrell K, Everson-Rose SA, Hess R, Matthews KA. Hot flashes and subclinical cardiovascular disease: findings from the Study of Women's Health Across the Nation Heart Study. Circulation 118, 1234-1240 (2008).
39. Bechlioulis A, Kalantaridou SN, Naka KK et al. Endothelial function, but not carotid intima-media thickness, is affected early in menopause and is associated with severity of hot flushes. J. Clin. Endocrinol. Metab. 95, 1199-1206 (2010).
40. Thurston RC, Sutton-Tyrrell K, Everson-Rose SA, Hess R, Powell LH, Matthews KA. Hot flashes and carotid intima media thickness among midlife women. Menopause 18, 352-358 (2011).
41. Ozkaya E, Cakir E, Kara F et al. Impact of hot flashes and night sweats on carotid intima-media thickness and bone mineral density among postmenopausal women. Int. J. Gynaecol. Obstet. 113, 235-238 (2011).
42. Tuomikoski P, Ebert P, Groop PH et al. Evidence for a role of hot flushes in vascular function in recently postmenopausal women. Obstet. Gynecol. 113, 902-908 (2009).
43. Rosenfeld ME, Kauser K, Martin-McNulty B, Polinsky P, Schwartz SM, Rubanyi GM. Estrogen inhibits the initiation of fatty streaks throughout the vasculature but does not inhibit intra-plaque hemorrhage and the progression of established lesions in apolipoprotein E deficient mice. Atherosclerosis 164, 251-259 (2002). (Pubitemid 35223074)
44. Harman SM, Vittinghoff E, Brinton EA et al. Timing and duration of menopausal hormone treatment may affect cardiovascular outcomes. Am. J. Med. 124, 199-205 (2011).
45. Toh S, Hernández-Díaz S, Logan R, Rossouw JE, Hernán MA. Coronary heart disease in postmenopausal recipients of estrogen plus progestin therapy: does the increased risk ever disappear? A randomized trial. Ann. Intern. Med. 152, 211-217 (2010).
46. Mikkola TS, Clarkson TB. Estrogen replacement therapy, atherosclerosis, and vascular function. Cardiovasc. Res. 53, 605-619 (2002). (Pubitemid 34175253)
47. Mendelsohn ME, Karas RH. Molecular and cellular basis of cardiovascular gender differences. Science 308, 1583-1587 (2005). (Pubitemid 40807497)
48. Choi SD, Steinberg EM, Lee HH, Naftolin F. The timing hypothesis remains a valid explanation of differential cardioprotective effects of menopausal hormone treatment. Menopause 18, 230-236 (2011).
49. Lenfant F, Trémollières F, Gourdy P, Arnal JF. Timing of the vascular actions of estrogens in experimental and human studies: why protective early, and not when delayed? Maturitas 68, 165-173 (2011).
50. Wingrove CS, Garr E, Godsland IF, Stevenson JC. 17b estradiol enhances release of matrix metalloproteinase 2 from human vascular smooth muscle cells. Biochim. Biophys. Acta 1406, 169-174 (1998). (Pubitemid 28193070)
51. Stevenson JC. HRT and the primary prevention of cardiovascular disease. Maturitas 57, 31-34 (2007). (Pubitemid 46602887)
52. Naftolin F, Taylor HS, Karas R et al. Women's Health Initiative. The Women's Health Initiative could not have detected cardioprotective effects of starting hormone therapy during the menopausal transition. Fertil. Steril. 81, 1498-1501 (2004). (Pubitemid 38748989)
53. Hulley S, Grady D, Bush T et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA 280, 605-613 (1998). (Pubitemid 28502636)
54. Alexandersen P, Tankó LB, Bagger YZ, Qin G, Christiansen C. The long-term impact of 2-3 years of hormone replacement therapy on cardiovascular mortality and atherosclerosis in healthy women. Climacteric 9, 108-118 (2006).
55. Salpeter SR, Walsh JM, Greyber E, Salpeter EE. Brief report: coronary heart disease events associated with hormone therapy in younger and older women. A meta-analysis. J. Gen. Intern. Med. 21, 363-366 (2006).
56. Harman SM, Brinton EA, Cedars M et al. KEEPS: The Kronos Early Estrogen Prevention Study. Climacteric 8, 3-12 (2005). (Pubitemid 40675116)
57. Sare GM, Gray LJ, Bath PM. Association between hormone replacement therapy and subsequent arterial and venous vascular events: a meta-analysis. Eur. Heart J. 29, 2031-2041 (2008).
58. Renoux C, Dell'aniello S, Garbe E, Suissa S. Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study. BMJ 340, c2519 (2010).
59. Lobo RA, Clarkson TB. Different mechanisms for benefit and risk of coronary heart disease and stroke in early postmenopausal women: a hypothetical explanation. Menopause 18, 237-240 (2011).
60. Canonico M, Plu-Bureau G, Lowe GD, Scarabin PY. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. BMJ 336, 1227-1231 (2008). (Pubitemid 351809317)
61. Daly E, Vessey MP, Hawkins MM, Carson JL, Gough P, Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 348, 977-980 (1996). (Pubitemid 26340751)
62. Scarabin PY, Oger E, Plu-Bureau G. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 362, 428-432 (2003). (Pubitemid 36999704)
63. Renoux C, Dell'Aniello S, Suissa S. Hormone replacement therapy and the risk of venous thromboembolism: a population-based study. J. Thromb. Haemost. 8, 979-986 (2010).
64. Canonico M, Fournier A, Carcaillon L et al. Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study. Arterioscler. Thromb. Vasc. Biol. 30, 340-345 (2010).
65. Godsland IF. Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974-2000. Fertil. Steril. 75, 898-915 (2001).
66. Sumino H, Ichikawa S, Kasama S et al. Different effects of oral conjugated estrogen and transdermal estradiol on arterial stiffness and vascular inflammatory markers in postmenopausal women. Atherosclerosis 189, 436-442 (2006). (Pubitemid 44634490)
67. Ho JY, Chen MJ, Sheu WH et al. Differential effects of oral conjugated equine estrogen and transdermal estrogen on atherosclerotic vascular disease risk markers and endothelial function in healthy postmenopausal women. Hum. Reprod. 21, 2715-2720 (2006). (Pubitemid 44542169)
68. Kanaya AM, Herrington D, Vittinghoff E et al. Heart and Estrogen/Progestin Replacement Study. Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/Progestin Replacement Study. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 138, 1-9 (2003). (Pubitemid 36232088)
69. Margolis KL, Bonds DE, Rodabough RJ et al.; Women's Health Initiative Investigators. Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women's Health Initiative Hormone Trial. Diabetologia 47, 1175-1187 (2004). (Pubitemid 39093314)
70. Rossi R, Origliani G, Modena MG. Transdermal 17b estradiol and risk of developing Type 2 diabetes in a population of healthy, nonobese postmenopausal women. Diabetes Care 28, 645-649 (2004). (Pubitemid 38280527)
71. Stevenson JC. A woman's journey through the reproductive, transitional and postmenopausal periods of life: impact on cardiovascular and musculo-skeletal risk and the role of estrogen replacement. Maturitas 70, 197-205 (2011).
72. Adams MR, Register TC, Golden DL, Wagner JD, Williams JK. Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 17, 217-221 (1997). (Pubitemid 27057346)
73. Archer DF, Thorneycroft IH, Foegh M et al. Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial. Menopause 12, 716-727 (2005). (Pubitemid 41669124)
74. Miyagawa K, Rösch J, Stanczyk F, Hermsmeyer K. Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm. Nat. Med. 3, 324-327 (1997). (Pubitemid 27112931)
75. Stevenson JC. Lipid metabolism. In: Hormone Replacement Therapy and Cardiovascular Disease. Genazzani AR (Ed.). Parthenon Publishing, Carnforth, UK, 27-35 (2001).
76. Crook D, Godsland IF, Hull J et al. Hormone replacement therapy with dydrogesterone and oestradiol 17b: effects on serum lipoproteins and glucose tolerance. Br. J. Obstet. Gynaecol. 104, 298-304 (1997). (Pubitemid 27112660)
77. Koh KK, Ahn JY, Jin DK et al. Significant differential effects of hormone therapy or tibolone on markers of cardiovascular disease in postmenopausal women: a randomized, double-blind, placebo-controlled, crossover study. Arterioscler. Thromb. Vasc. Biol. 23, 1889-1894 (2003). (Pubitemid 37254880)
78. Bots ML, Evans GW, Riley W et al.; OPAL Investigators. The effect of tibolone and continuous combined conjugated equine oestrogens plus medroxyprogesterone acetate on progression of carotid intima-media thickness: the Osteoporosis Prevention and Arterial effects of tiboLone (OPAL) study. Eur. Heart J. 27, 746-755 (2006).
79. Zandberg P, Peters JL, Demacker PN, Smit MJ, de Reeder EG, Meuleman DG. Tibolone prevents atherosclerotic lesion formation in cholesterol-fed, ovariectomized rabbits. Arterioscler. Thromb. Vasc. Biol. 18, 1844-1854 (1998). (Pubitemid 28565745)
80. Clarkson TB, Anthony MS, Cline JM, Lees CJ, Ederveen AG. Multisystem evaluations of the long-term effects of tibolone on postmenopausal monkeys. Maturitas 48(Suppl. 1), S24-S29 (2004). (Pubitemid 39141191)
81. Silvestri A, Gambacciani M, Vitale C et al. Different effect of hormone replacement therapy, DHEAS and tibolone on endothelial function in postmenopausal women with increased cardiovascular risk. Maturitas 50, 305-311 (2005). (Pubitemid 40365035)
82. Cummings SR, Ettinger B, Delmas PD et al.; LIFT Trial Investigators. The effects of tibolone in older postmenopausal women. N. Engl. J. Med. 359, 697-708 (2008).
83. McDonald CC, Alexander FE, Whyte BW, Forrest AP, Stewart HJ. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomized trial. BMJ 311, 977-980 (1995).
84. Fisher B, Costantino JP, Wickerham DL et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P 1 Study. J. Natl Cancer Inst. 90, 1371-1388 (1998). (Pubitemid 28439961)
85. Williams JK, Wagner JD, Li Z, Golden DL, Adams MR. Tamoxifen inhibits arterial accumulation of LDL degradation products and progression of coronary artery atherosclerosis in monkeys. Arterioscler. Thromb. Vasc. Biol. 17, 403-408 (1997). (Pubitemid 27098200)
86. Blumenthal RS, Baranowski B, Dowsett SA. Cardiovascular effects of raloxifene: the arterial and venous systems. Am. Heart J. 147, 783-789 (2004). (Pubitemid 38880982)
87. Simoncini T, Genazzani AR, Liao JK. Nongenomic mechanisms of endothelial nitric oxide synthase activation by the selective estrogen receptor modulator raloxifene. Circulation 105, 1368-1373 (2002). (Pubitemid 34260430)
88. Barrett-Connor E, Mosca L, Collins P et al.; Raloxifene Use for The Heart (RUTH) Trial Investigators. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N. Engl. J. Med. 355, 125-137 (2006). (Pubitemid 44050394)
89. Collins P, Mosca L, Geiger MJ et al. Effects of the selective estrogen receptor modulator raloxifene on coronary outcomes in the Raloxifene Use for The Heart trial: results of subgroup analyses by age and other factors. Circulation 119, 922-930 (2009).
90. Cummings SR, Ensrud K, Delmas PD et al.; PEARL Study Investigators. Lasofoxifene in postmenopausal women with osteoporosis. N. Engl. J. Med. 362, 686-696 (2010).
91. Lobo RA, Pinkerton JV, Gass ML et al. Evaluation of bazedoxifene/ conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile. Fertil. Steril. 92, 1025-1038 (2009).
92. Chambliss KL, Shaul PW. Estrogen modulation of endothelial nitric oxide synthase. Endocr. Rev. 23, 665-686 (2002). (Pubitemid 35191628)
93. Wingrove CS, Stevenson JC. 17b estradiol inhibits stimulated endothelin release in human vascular endothelial cells. Eur. J. Endocrinol. 137, 205-208 (1997). (Pubitemid 27342238)
94. Collins P, Rosano GM, Sarrel PM et al. 17b estradiol attenuates acetylcholine-induced coronary arterial constriction in women but not men with coronary heart disease. Circulation 92, 24-30 (1995).
95. Geraldes P, Sirois MG, Bernatchez PN, Tanguay JF. Estrogen regulation of endothelial and smooth muscle cell migration and proliferation: role of p38 and p42/44 mitogen-activated protein kinase. Arterioscler. Thromb. Vasc. Biol. 22, 1585-1590 (2002).
96. Tharakan B, Corprew R, Hunter FA, Whaley JG, Smythe WR, Childs EW. 17b estradiol mediates protection against microvascular endothelial cell hyperpermeability. Am. J. Surg. 197, 147-154 (2009).
97. Florian M, Magder S. Estrogen decreases TNF a and oxidized LDL induced apoptosis in endothelial cells. Steroids 73, 47-58 (2008). (Pubitemid 350245674)
98. Jayachandran M, Mukherjee R, Steinkamp T et al. Differential effects of 17b estradiol, conjugated equine estrogen, and raloxifene on mRNA expression, aggregation, and secretion in platelets. Am. J. Physiol. Heart Circ. Physiol. 288, H2355-H2362 (2005).
99. Egan KM, Lawson JA, Fries S et al. COX 2-derived prostacyclin confers atheroprotection on female mice. Science 306, 1954-1957 (2004). (Pubitemid 39627863)
100. Störk S, von Schacky C, Angerer P. The effect of 17b estradiol on endothelial and inflammatory markers in postmenopausal women: a randomized, controlled trial. Atherosclerosis 165, 301-307 (2002). (Pubitemid 35333356)
101. Guzic-Salobir B, Keber I, Seljeflot I, Arnesen H, Vrabic L. Combined hormone replacement therapy improves endothelial function in healthy postmenopausal women. J. Intern. Med. 250, 508-515 (2001). (Pubitemid 34008761)
102. Eilertsen AL, Hoibraaten E, Os I, Andersen TO, Sandvik L, Sandset PM. The effects of oral and transdermal hormone replacement therapy on C reactive protein levels and other inflammatory markers in women with high risk of thrombosis. Maturitas 52, 111-118 (2005). (Pubitemid 41368033)
103. Sumino H, Ichikawa S, Kasama S et al. Effect of transdermal hormone replacement therapy on carotid artery wall thickness and levels of vascular inflammatory markers in postmenopausal women. Hypertens. Res. 28, 579-584 (2005). (Pubitemid 41387288)